Liquid biopsy-based circulating tumour (ct)DNA analysis of a spectrum of myeloid and lymphoid malignancies yields clinically actionable results
© 2024 John Wiley & Sons Ltd..
AIMS: Liquid biopsy (LBx)-based next-generation sequencing (NGS) of circulating tumour DNA (ctDNA) can facilitate molecular profiling of haematopoietic neoplasms (HNs), particularly when tissue-based NGS is infeasible.
METHODS AND RESULTS: We studied HN LBx samples tested with FoundationOne Liquid CDx, FoundationOne Liquid, or FoundationACT between July 2016 and March 2022. We identified 271 samples: 89 non-Hodgkin lymphoma (NHL), 43 plasma-cell neoplasm (PCN), 41 histiocytoses, 27 myelodysplastic syndrome (MDS), 25 diffuse large B-cell lymphoma (DLBCL), 22 myeloproliferative neoplasm (MPN), 14 Hodgkin lymphoma (HL), and 10 acute myeloid leukaemia (AML). Among 73.4% with detectable pathogenic alterations, median maximum somatic allele frequency (MSAF) was 16.6%, with AML (36.2%), MDS (19.7%), and MPN (44.5%) having higher MSAFs than DLBCL (3.9%), NHL (8.4%), HL (1.5%), PCN (2.8%), and histiocytoses (1.8%) (P = 0.001). LBx detected characteristic alterations across HNs, including in TP53, KRAS, MYD88, and BTK in NHLs; TP53, KRAS, NRAS, and BRAF in PCNs; IGH in DLBCL; TP53, ATM, and PDCD1LG2 in HL; BRAF and MAP2K1 in histiocytoses; TP53, SF3B1, DNMT3A, TET2, and ASXL1 in MDS; JAK2 in MPNs; and FLT3, IDH2, and NPM1 in AML. Among 24 samples, the positive percent agreement by LBx was 75.7% for variants present in paired buffy coat, marrow, or tissues. Also, 75.0% of pairs exhibited alterations only present on LBx. These were predominantly subclonal (clonal fraction of 3.8%), reflecting the analytical sensitivity of LBx.
CONCLUSION: These data demonstrate that LBx can detect relevant genomic alterations across HNs, including at low clonal fractions, suggesting a potential clinical utility for identifying residual or emerging therapy-resistant clones that may be undetectable in site-specific tissue biopsies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:84 |
|---|---|
| Enthalten in: |
Histopathology - 84(2024), 7 vom: 17. Apr., Seite 1224-1237 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mata, Douglas A [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
117896-08-9 |
|---|
| Anmerkungen: |
Date Completed 24.04.2024 Date Revised 24.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/his.15168 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369125126 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369125126 | ||
| 003 | DE-627 | ||
| 005 | 20240425233018.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240301s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/his.15168 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1386.xml |
| 035 | |a (DE-627)NLM369125126 | ||
| 035 | |a (NLM)38422618 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mata, Douglas A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Liquid biopsy-based circulating tumour (ct)DNA analysis of a spectrum of myeloid and lymphoid malignancies yields clinically actionable results |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.04.2024 | ||
| 500 | |a Date Revised 24.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024 John Wiley & Sons Ltd. | ||
| 520 | |a AIMS: Liquid biopsy (LBx)-based next-generation sequencing (NGS) of circulating tumour DNA (ctDNA) can facilitate molecular profiling of haematopoietic neoplasms (HNs), particularly when tissue-based NGS is infeasible | ||
| 520 | |a METHODS AND RESULTS: We studied HN LBx samples tested with FoundationOne Liquid CDx, FoundationOne Liquid, or FoundationACT between July 2016 and March 2022. We identified 271 samples: 89 non-Hodgkin lymphoma (NHL), 43 plasma-cell neoplasm (PCN), 41 histiocytoses, 27 myelodysplastic syndrome (MDS), 25 diffuse large B-cell lymphoma (DLBCL), 22 myeloproliferative neoplasm (MPN), 14 Hodgkin lymphoma (HL), and 10 acute myeloid leukaemia (AML). Among 73.4% with detectable pathogenic alterations, median maximum somatic allele frequency (MSAF) was 16.6%, with AML (36.2%), MDS (19.7%), and MPN (44.5%) having higher MSAFs than DLBCL (3.9%), NHL (8.4%), HL (1.5%), PCN (2.8%), and histiocytoses (1.8%) (P = 0.001). LBx detected characteristic alterations across HNs, including in TP53, KRAS, MYD88, and BTK in NHLs; TP53, KRAS, NRAS, and BRAF in PCNs; IGH in DLBCL; TP53, ATM, and PDCD1LG2 in HL; BRAF and MAP2K1 in histiocytoses; TP53, SF3B1, DNMT3A, TET2, and ASXL1 in MDS; JAK2 in MPNs; and FLT3, IDH2, and NPM1 in AML. Among 24 samples, the positive percent agreement by LBx was 75.7% for variants present in paired buffy coat, marrow, or tissues. Also, 75.0% of pairs exhibited alterations only present on LBx. These were predominantly subclonal (clonal fraction of 3.8%), reflecting the analytical sensitivity of LBx | ||
| 520 | |a CONCLUSION: These data demonstrate that LBx can detect relevant genomic alterations across HNs, including at low clonal fractions, suggesting a potential clinical utility for identifying residual or emerging therapy-resistant clones that may be undetectable in site-specific tissue biopsies | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a haematopathology | |
| 650 | 4 | |a liquid biopsy | |
| 650 | 4 | |a next‐generation sequencing | |
| 650 | 7 | |a Circulating Tumor DNA |2 NLM | |
| 650 | 7 | |a Biomarkers, Tumor |2 NLM | |
| 650 | 7 | |a Nucleophosmin |2 NLM | |
| 650 | 7 | |a 117896-08-9 |2 NLM | |
| 700 | 1 | |a Lee, Jessica K |e verfasserin |4 aut | |
| 700 | 1 | |a Shanmugam, Vignesh |e verfasserin |4 aut | |
| 700 | 1 | |a Marcus, Chelsea B |e verfasserin |4 aut | |
| 700 | 1 | |a Schrock, Alexa B |e verfasserin |4 aut | |
| 700 | 1 | |a Williams, Erik A |e verfasserin |4 aut | |
| 700 | 1 | |a Ritterhouse, Lauren L |e verfasserin |4 aut | |
| 700 | 1 | |a Hickman, Richard A |e verfasserin |4 aut | |
| 700 | 1 | |a Janovitz, Tyler |e verfasserin |4 aut | |
| 700 | 1 | |a Patel, Nimesh R |e verfasserin |4 aut | |
| 700 | 1 | |a Kroger, Benjamin R |e verfasserin |4 aut | |
| 700 | 1 | |a Ross, Jeffrey S |e verfasserin |4 aut | |
| 700 | 1 | |a Mirza, Kamran M |e verfasserin |4 aut | |
| 700 | 1 | |a Oxnard, Geoffrey R |e verfasserin |4 aut | |
| 700 | 1 | |a Vergilio, Jo-Anne |e verfasserin |4 aut | |
| 700 | 1 | |a Elvin, Julia A |e verfasserin |4 aut | |
| 700 | 1 | |a Benhamida, Jamal K |e verfasserin |4 aut | |
| 700 | 1 | |a Decker, Brennan |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Mina L |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Histopathology |d 1985 |g 84(2024), 7 vom: 17. Apr., Seite 1224-1237 |w (DE-627)NLM000284408 |x 1365-2559 |7 nnns |
| 773 | 1 | 8 | |g volume:84 |g year:2024 |g number:7 |g day:17 |g month:04 |g pages:1224-1237 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/his.15168 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 84 |j 2024 |e 7 |b 17 |c 04 |h 1224-1237 | ||